Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches

Credits Available:

3.0 AMA PRA Category 1 Credits™, 3.0 ANCC Contact Hours, 3.0 ACPE Contact Hours

• Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches - Baseline Assessment

  In this section, we will ask a series of questions regarding treatment and adverse event management strategies for patients with AML. We will ask the questions twice: at Baseline and Final. These questions are intended to help gauge the educational impact of this program.

• Self Study Module 1 - Frontline Therapy for Patients With AML Without Targetable Mutations

  In this interactive video presentation, Dr. Eunice Wang presents optimal management strategies for patients who present with treatment-naive AML.

• Self Study Module 2 - Therapy for Patients With AML With Targetable Mutations

  Dr. Amir Fathi highlights key treatment approaches for patients with AML with targetable mutations in this interactive video presentation.

• Self Study Module 3 - Maintenance Therapy in Patients With AML

  Dr. Eunice Wang presents treatment strategies with maintenance therapies for patients with AML in complete remission who are ineligible for or decline stem cell transplantation.

• Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches - Final Assessment

  In this section, we will ask a series of questions regarding treatment and adverse event management strategies for patients with AML. We will ask the questions twice: at Baseline and Final. These questions are intended to help gauge the educational impact of this program.

• Improving Patient Care for Patients With AML

  This live discussion will offer an expert-led, interactive approach to providing care for patients with AML. Topics discussed will include creating and implementing optimal strategies for treatment selection for patients with AML and managing treatment-related adverse events.

• Treatment Approaches for Patients With Treatment-Naive or Relapsed/Refractory AML With or Without Targetable Mutations

  This live, interactive discussion will focus on reviewing patient cases and group tasks assigned in the first discussion and how the findings can apply to improving care for patients with treatment-naive and relapsed/refractory acute myeloid leukemia, with and without targetable mutations.

• Group Task Case #1 - Mrs. Jenkins, a 79-yr-old woman

  The following case challenge presents Mrs. Jenkins, an elderly patient with AML and significant comorbidities. The group objective of this segment is to explore all aspects of disease management in this patient with newly diagnosed AML.

• Group Task Case #2 - Mr. Tyler, a 68-yr-old man

  This case challenge presents Mr. Tyler, a 68-year-old man with relapsed/refractory AML with a FLT3 mutation. The group objective of this segment is to discuss optimal treatment and AE management strategies for this patient.

Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.

View Other Offerings